Miragen Therapeutics (MGEN) Scheduled to Post Earnings on Wednesday

Miragen Therapeutics (NASDAQ:MGEN) will release its earnings data after the market closes on Wednesday, August 7th. Analysts expect Miragen Therapeutics to post earnings of ($0.37) per share for the quarter.

Miragen Therapeutics (NASDAQ:MGEN) last announced its quarterly earnings results on Wednesday, May 8th. The medical research company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). Miragen Therapeutics had a negative return on equity of 71.91% and a negative net margin of 998.26%. The company had revenue of $0.37 million during the quarter, compared to the consensus estimate of $1.35 million. On average, analysts expect Miragen Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of MGEN stock opened at $2.04 on Wednesday. The business has a 50 day moving average of $2.22. Miragen Therapeutics has a 52 week low of $1.91 and a 52 week high of $7.04. The company has a market capitalization of $63.10 million, a price-to-earnings ratio of -1.85 and a beta of 1.16. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.90 and a quick ratio of 7.90.

Several analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of General Moly from a “sell” rating to a “hold” rating in a research report on Thursday, July 11th. Wedbush restated a “buy” rating and set a $24.00 target price on shares of Miragen Therapeutics in a research report on Tuesday, May 21st. Finally, ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. Miragen Therapeutics presently has an average rating of “Buy” and a consensus price target of $16.00.

Miragen Therapeutics Company Profile

Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.

Read More: P/E Growth (PEG)

Earnings History for Miragen Therapeutics (NASDAQ:MGEN)

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.